单剂赛尼哌预防肾移植术后急性排斥反应的临床研究  

A single-dose Zenapax induction therapy in renal transplant recipients

作　　者：黄辉[1] 曾涛[1] 孟栋良[1] 李新长[1] 

机构地区：[1]江西省人民医院泌尿外科,南昌330006

出　　处：《江西医药》2009年第3期207-209,共3页Jiangxi Medical Journal

摘　　要：目的探讨赛尼哌（CD25单克隆抗体）单剂给药在肾移植术后预防急性排斥反应中的作用。方法将2002年1月-2005年10月在我科接受肾移植80例患者,随机分为2组,即赛尼哌治疗组（观察组n=40）和常规治疗组（对照组n=40）,两组之间年龄、性别、术前血透时间、热缺血时间、冷缺血时间、补体依赖性细胞毒试验（CDC）、群体反应抗体（PRA）水平均无显著性差异。所有患者术后免疫抑制治疗为环孢素A（CsA）＋骁悉（MMF）＋泼尼松（Pred）三联疗法,观察组在三联免疫抑制基础上加用赛尼哌。观察两组术后半年急性排斥发生情况、移植肾功能及毒副作用。结果观察组中4例（10%）患者出现急性排斥反应,对照组中8例（20%）患者出现急性排斥反应,观察组急性排斥反应明显低于对照组,有显著性差异（P〈0.05）。同时,两组未发生细胞因子释放综合征;观察组并没有增加肺部感染的机会。结论肾移植受者应用赛尼哌单剂诱导治疗可降低肾移植术后急性排斥反应发生率。Objective To investigate a single dose Zenapax to prevent acute rejection in renal transplant recipients.Methods A total of 80 patients undergone renal transplant from Jan 2002 to Oct 2005 were randomized into Zenapax group（n=40） and control group（n=40）.No significant difference were marked between the 2 groups in terms of age,sex,dialysis time before operation,warm ischemia time,cold isehemia time,complement dependent cytotoxicity（CDC） and penal reactive antibody （PRA）.Main immunosuppressive therapy regimen consisted of steiods,Cyclosporine A and myeophenelate mofetil （MMF） in all recipients.Results During a 6- month follow-up,4 cases were subjected to acute rejection in Zenapax group and 8 in control group （P〈0.05）.No cytokine release syndrome occurred in both groups. Zenapax group did not comprise more risk of lung infection compared with the control group.Conclusion A single-dose Zenapax therapy can reduces the frequency of acute rejection in renal transplant recipients.

关 键 词：肾移植 赛尼哌 免疫诱导 排斥反应 

分 类 号：R699.2[医药卫生—泌尿科学]